Related Experiment Video

Updated: Jun 22, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

[Sorafenib(Nexavar)]

Naoto Miyanaga1, Hideyuki Akaza

  • 1Dept. of Urology, Institute of Clinical Medicine, Post- Graduate University of Tsukuba, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|June 23, 2009
PubMed

Insights

Sorafenib (Nexavar) is a multikinase inhibitor that significantly prolonged progression-free survival in patients with advanced renal cell carcinoma. This targeted therapy demonstrated comparable efficacy and manageable side effects in elderly patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Sorafenib (Nexavar) is an orally administered multikinase inhibitor targeting intracellular and extracellular receptors.
  • Advanced renal cell carcinoma (RCC) presents a significant therapeutic challenge.

Purpose of the Study:

  • To evaluate the efficacy and safety of sorafenib in patients with advanced renal cell carcinoma (RCC) who have failed prior therapy.

Main Methods:

  • Phase III clinical trial comparing sorafenib to placebo in patients with advanced RCC.
  • Assessment of progression-free survival (PFS) as the primary endpoint.
  • Monitoring of adverse events and subgroup analysis in elderly patients.

Main Results:

  • Sorafenib significantly prolonged progression-free survival (PFS) compared to placebo.
  • Common adverse events included diarrhea, rash, fatigue, hand-foot skin reactions, and hypertension.
  • Sorafenib showed comparable response rates and manageable side effects in elderly patients.

Conclusions:

  • Sorafenib is an effective treatment for advanced renal cell carcinoma (RCC), offering prolonged PFS.
  • The drug is well-tolerated in elderly populations, with manageable side effects.
  • Sorafenib is a recommended standard of care for advanced RCC, with ongoing research needed for biomarkers and combination therapies.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...